Dr. Ania Jastreboff discusses the current use of anti-obesity pharmacotherapy, mechanisms involved, and agents in various stages of development with considerations for next steps.

Obesity is a treatable chronic disease. With nearly 2 billion individuals worldwide classified as being overweight and 650 million as having obesity, it is critical to optimize implementation of existing treatment interventions and develop novel therapies to mitigate the obesity pandemic. Anti-obesity medications are one of the essential tools in our medical toolbox to help patients achieve their health and weight goals.

In this webinar, Dr. Jastreboff will discuss current use of anti-obesity pharmacotherapy, mechanisms involved, and agents in various stages of development with considerations for next steps. The presentation aims to inspire development of innovative therapeutics while optimizing use of existing agents to address the urgent need to effectively and sustainably treat millions of individuals with obesity around the world.

Key Topics Include:

  • Understand the role of anti-obesity pharmacotherapy in the treatment of obesity
  • Describe current anti-obesity pharmacotherapy
  • Discuss anti-obesity medications under development

Presenters

Associate Professor, Director, Weight Management & Obesity Prevention, Yale Stress Center
School of Medicine
Yale University

Dr. Jastreboff is an Obesity Medicine physician, board certified in Obesity Medicine, adult Endocrinology and Metabolism, and Pediatric Endocrinology. She is nationally and internationally recognized in the Obesity Medicine field for developing Clinical Practice Guidelines (2016) for The Comprehensive Care of Patients with Obesity (AACE/ACE), educating the next generation of Obesity Medicine physicians by teaching annually at the world renowned Harvard Blackburn Treating Obesity course and the Columbia/Cornell Obesity course, and conducting cutting-edge clinical translational obesity research. Her research includes both large, multi-center clinical outcomes trials using anti-obesity medication as well as neuroimaging studies (fMRI and PET) examining the neurobiology underlying obesity and the mechanisms of anti-obesity medications.